Proceedings from the 1^st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016

1. THE LANCET HAEMATOLOGY. A roadmap for European research. Lancet Haematol. 2016; 3(3):e99.10.1016/S2352-3026(16)00025-9Search in Google Scholar

2. TOMULEASA C., FUJI S., CUCUIANU A., KAPP M., PILECZKI V., PETRUSHEV B., et al. MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. Ann Hematol. 2015; 94(7):1081-92.10.1007/s00277-015-2369-025900787Search in Google Scholar

3. BRAICU C., TOMULEASA C., MONROIG P., CUCUIANU A., BERINDAN-NEAGOE I., CALIN G.A. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015; 22(1):34-45.10.1038/cdd.2014.130426277725236394Search in Google Scholar

4. BERINDAN-NEAGOE I., MONROIG P DEL C., PASCULLI B., CALIN G.A. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64(5):311-36.10.3322/caac.21244446119825104502Search in Google Scholar

5. TOMULEASA C., AKIN-ABAYOMI E., DIMA D., TEFAS C., IRIMIE A., PETRUSHEV B., et al. Do lymphomas have an autoimmune background and how can we increase the sensitivity of the diagnosis of primary pancreatic lymphoma with relatively small samples? J Gastrointestin Liver Dis. 2015; 24(3):391-2.Search in Google Scholar

6. GREWAL R., CUCUIANU A., SWANEPOEL C., DIMA D., PETRUSHEV B., POP B., et al. The role of microRNAs in the pathogenesis of HIV-related lymphomas. Crit Rev Clin Lab Sci. 2015; 52(5):232-41.10.3109/10408363.2015.103006326218036Search in Google Scholar

7. BRAMMER J.E., KHOURI I., GABALLA S., ANDERLINI P., TOMULEASA C., AHMED S., et al. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016; 22(3):493-8.10.1016/j.bbmt.2015.10.01526497906Search in Google Scholar

8. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., ORBAN C., et al. Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease? Acta Haematol. 2016; 135(4):211-216.10.1159/00044346926914538Search in Google Scholar

9. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., CIUREA S.O. First successful haploidentical stem cell transplantation in Romania. Rom J Intern Med 2016, in press.10.1515/rjim-2016-0021725221627658169Search in Google Scholar

10. PETRUSHEV B., BOCA S., SIMON T., BERCE C., FRINC I., DIMA D., et al. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine. 2016; 11:641-60.Search in Google Scholar

11. SUARASAN S., SIMON T., BOCA S., TOMULEASA C., ASTILEAN S. Gelatin coated gold nanoparticles as carriers of FLT3 inhibitors for acute myeloid leukemia treatment. Chem Biol Drug Des. 2016; doi: 10.1111/cbdd.12725.Search in Google Scholar

12. SIMON T., TOMULEASA C., BOJAN A., BERINDAN-NEAGOE I., BOCA S., ASTILEAN S. Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Res Lett. 2015; 10(1):466.10.1186/s11671-015-1154-2466684526625890Search in Google Scholar

13. CIUREA S.O., ZHANG M.J., BACIGALUPO A.A., BASHEY A., APPELBAUM F.R., ALJITAWI O.S., et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015; 126(8):1033-40.10.1182/blood-2015-04-639831454322326130705Search in Google Scholar

14. TOMULEASA C., DIMA D., FRINC I., PATIU M., PETRUSHEV B., CUCUIANU A., et al. BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice. Leuk Lymphoma. 2015; 56(2):546-7.10.3109/10428194.2014.94058225012945Search in Google Scholar

15. ALONSO S., SU M., JONES J.W., GANGULY S., KANE M.A., JONES R.J., et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015; 6(17):14905-12.10.18632/oncotarget.3614455812425915157Search in Google Scholar

16. SU M., ALONSO S., JONES J.W., YU J., KANE M.A., JONES R.J., et al. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS One. 2015; 10(6):e0127790.10.1371/journal.pone.0127790445789326047326Search in Google Scholar

17. MCCORMACK E., HAALAND I., VENAS G., FORTHUN R.B., HUSEBY S., GAUSDAL G., et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012; 26(5):910-7.10.1038/leu.2011.31522064349Search in Google Scholar

18. MCCORMACK E., MUJIC M., OSDAL T., BRUSERUD Ø., GJERTSEN B.T. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013; 121(7):e34-42.10.1182/blood-2012-05-42955523243270Search in Google Scholar

19. TANASE A., SCHMITZ N., STEIN H., BOUMENDIL A., FINEL H., CASTAGNA L., et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia. 2015; 29(3):686-8.10.1038/leu.2014.28025234166Search in Google Scholar

20. TRIFA A.P., POPP R.A., CUCUIANU A., BANESCU C., TEVET M., MARTIN B., et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015; 168(1):151-3.10.1111/bjh.1307625103987Search in Google Scholar

21. TOMULEASA C., BRAICU C., IRIMIE A., CRACIUN L., BERINDAN-NEAGOE I. Nanopharmacology in translational hematology and oncology. Int J Nanomedicine. 2014; 9:3465-79.Search in Google Scholar